Dronabinol low-dose - RespireRx Pharmaceuticals

Drug Profile

Dronabinol low-dose - RespireRx Pharmaceuticals

Alternative Names: PP-001 - Pier

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pier Pharmaceuticals
  • Developer Northwestern University; RespireRx Pharmaceuticals; University of Chicago; University of Illinois
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Sleep apnoea syndrome

Most Recent Events

  • 19 Jun 2018 RespireRx Pharmaceuticals and Noramco signed a letter of intent for dronabinol
  • 30 Nov 2017 Updated efficacy data from the phase IIb PACE trial in Sleep apnoea syndrome released by RespireRx Pharmaceuticals
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Sleep-apnoea-syndrome(Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top